Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

Celularity Inc
Celularity Inc. (CELU) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001 created for the treatment of acute myeloid leukemia (AML).

Headquartered in Florham Park, N.J., Celularity is a clinical . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.